Novartis has tapped up an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for ...

"Novartis and UK-based Relation forge R&D deal worth up to $1.7bn" was originally created and published by Pharmaceutical ...

Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences Read more at The ...

Investing.com -- Swiss pharmaceutical company Novartis AG (SIX:NOVN) has entered into a partnership with UK-based Relation Therapeutics Ltd., potentially worth up to $1.7 billion, to accelerate the ...

The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...

Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms of the agreement, Relation will receive $55 ...

Novartis AG (NVS) to pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat ...

Relation's draw is its 'lab-in-a-loop' process of AI-driven target and drug discovery, in which algorithms are used to find ...

Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis to discover and advance novel targets for atopic diseases.

Novartis is teaming up with Microsoft on a new artificial intelligence initiative focused on drug discovery and development. The new efforts will primarily be focused in Novartis’ newly announced AI ...

Novartis operates globally in pharmaceuticals, focusing on therapeutic development, clinical research, and manufacturing, ...

Novartis AG will pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases.